With the COVID-19 epidemic escalating in France, the government is pivoting to widespread testing. Here's how they plan to scale up screening efforts effectively.
Germany has achieved a low mortality rate of just 0.5%—far below neighbors like Italy, Spain, and France—thanks to conducting around half a million diagnostic tests weekly in labs.
As reported by Ouest-France on March 29, 2020, France has placed a substantial order for screening tests. Key details include: What type of tests are these, and how do they function?
The primary method is the PCR test, a proven molecular biology technique that detects the COVID-19 virus from patient samples. It involves a nasal swab to collect deep nasal cells, with results typically available in 3 to 6 hours.
Previously limited to specialized labs, these tests can now be performed by a broader range of facilities, including genetics, medical biology, and research labs. While reagent and swab shortages have occurred, new suppliers are entering the market to stabilize supply chains.
Health Minister Olivier Véran reported 12,000 PCR tests conducted on March 28 alone—double the previous week's daily average of about 5,000. Tests require a medical prescription, though the Academy of Medicine advocates testing any suspected cases.
The government has also ordered serological tests that detect IGM and IGG antibodies produced by the body against COVID-19. These emerge 3 to 15 days post-infection, so early testing may yield less reliable results.
France aims for 100,000 tests per day by late June. As of March 29 evening, the country reported 40,723 cases and 2,606 deaths, ranking 5th globally in COVID-19 impact.
